New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Alpine, Apexigen, Basilea, Biopath, CG, Chemocentryx, Cstone, Deciphera, Erasca, Gritstone, Highlight, Kineta, Mustang, Neoimmunetech, Neoleukin, Oric, Portage, Sotio, Trishula.
The tumor microenvironment is critical for the ability of cancers to survive and grow, and some aspects of the microenvironment are studied, and targeted, accordingly. Tumor immunology is one of the most active areas of cancer research and has become a pillar of treatment. Others, not so much. “The nervous system is the last component of the microenvironment that people have left completely unrecognized,” Humsa Venkatesh told BioWorld. Even in brain tumors and metastases, where the presence of neurons is glaringly obvious, there has been little attention to how the two interact until recently.
“We’re still a far cry from reproducible, durable benefits” with CAR T cells targeting solid tumors, Crystal Mackall told the audience at the 2022 annual meeting of the American Association for Cancer Research (AACR). But “we’re beginning to see some signals.” Mackall is the founding director of the Stanford Center for Cancer Cell Therapy.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Abbvie, Aptevo, Harpoon, Jubilant, Kura, Kamera, MEI, Perus, Mina, Moleculin, Myeloid, Natera, Nimbus, Nktarta, Nouscom, Nurix, Nuvalent, Nuvectis, Omega, Obsidian, Oncolytic.
Oncology specialist Affimed NV is pushing forward with clinical development of technology that encourages natural killer cells to attack solid tumors. The move, supported by data the company presented at the annual meeting of the American Association for Cancer Research (AACR), is backing its creation of “innate cell engager” molecules.
With 11 approved therapeutics in a diversity of targets and indications, antibody-drug conjugates (ADCs) have proved their clinical mettle. But they have not yet reached their full clinical potential, which, in the opinion of Astrazeneca plc’s Kenneth Thress, could transform patient care. The strength of ADCs, he told the audience at an educational session at the 2022 annual meeting of the American Association for Cancer Research (AACR 2022), is that it can turn anything into a targeted therapy.
Investigators at Weill Cornell Medical College have identified propionate metabolism as a contributor to the ability of cancer cells to establish metastases, establishing new basic insights into cancer metastases as well as potential therapeutic targets.
With the advent of targeted therapies, cancer drugs have made strides in safety as well as efficacy. Still, because of the life threatening nature of the illness, safety is less of a focus in cancer drugs than other therapy types.
RSS
